Toxicity, recurrence and survival after adjuvant radiotherapy treatment for FIGO stage I cancer of the endometrium

被引:3
|
作者
Moss, EL
Stevens, A
Gray, L
McConkey, C
Fernando, I
机构
[1] Univ Hosp, Dept Clin Oncol, Birmingham, W Midlands, England
[2] Univ Birmingham, Canc Res UK Clin Trials Unit, Birmingham, W Midlands, England
关键词
adjuvant radiotherapy; vaginal vault brachytherapy; endometrial cancer; recurrence; survival; toxicity;
D O I
10.1016/S0936-6555(03)00149-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We conducted a retrospective observational study to determine the rate of toxicity, pattern of tumour recurrence and survival associated with radiotherapy treatment for FIGO stage I cancer of the endometrium. All patients had undergone definitive surgery and had been referred to the oncology department of the University Hospital Birmingham, U.K. Two hundred and forty-five women were included in the study; 228 patients were treated with radiotherapy; 160 had external beam radiation alone; 32 had vaginal vault brachytherapy alone; 36 patients had both modalities; and 17 patients were not given radiotherapy. There were nine cases of Grade 3 and 4 radiation reactions, of which four were acute, four were late and one was acute and late toxicity. The severity of both acute and late radiation effects was significantly associated with the delivery of vault brachytherapy (external beam radiotherapy alone compared with brachytherapy alone (1/158 vs 3/32; P=0.02). Thirty-four patients were diagnosed with tumour recurrence (11 distant, 14 local, 4 patients had both distant and local disease and 5 patients had recurrence diagnosed at the time of death). Patients who received no radiotherapy were at greater risk of local pelvic tumour recurrence (P<0.0001; hazard ratio [HR] 9.6, 95% confidence interval (CI) 3.5-26.3). Vaginal vault brachytherapy had no discernible effect on the pattern of tumour recurrence. Forty-six patients died during the follow-up period, 28 of these were attributable to carcinoma of the endometrium. There was no difference in survival between the four treatment groups (P=0.68). The overall 5-year survival rate in our study group was 89.6% (85.4-93.8%). In a proportional hazards model, tumour grade (HR 2.0 per level [1.25, 3.17]; P=0.004]) and age (HR 1.74 per 10 years [1.12, 2.69]; P=0.01) were the only factors found to have an independent influence on survival. This study suggests that, although pelvic radiation may not alter overall survival, it does reduce the risk of local disease recurrence. In this study population, vaginal vault brachytherapy using a vaginal stock/dobbie showed no additional benefits compared with external beam radiotherapy; it was, however, associated with a higher rate of both acute and late radiation effects. (C) 2003 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:250 / 254
页数:5
相关论文
共 50 条
  • [31] Effect of adjuvant radiotherapy on local recurrence in stage II rectal cancer
    Park, In Ja
    Kim, Hee Cheol
    Yu, Chang Sik
    Kim, Tae Won
    Jang, Se Jin
    Kim, Jin Cheon
    ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (02) : 519 - 525
  • [32] RISK FACTORS FOR RECURRENCE AFTER RADIOTHERAPY IN FIGO STAGE IB1 AND IIA1 CERVICAL CANCER
    Yokoyama, T.
    Shinichi, O.
    Tamaki, T.
    Etsuko, F.
    Katsuyuki, T.
    Mika, O. S.
    Takashi, Y.
    Kazuhiro, T.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 444 - 444
  • [33] Is there a survival benefit to adjuvant radiotherapy in high-risk surgical stage I endometrial cancer?
    Ayhan, A
    Taskiran, C
    Celik, C
    Guney, I
    Yuce, K
    Ozyar, E
    Atahan, L
    Kucukali, T
    GYNECOLOGIC ONCOLOGY, 2002, 86 (03) : 259 - 263
  • [34] Vaginal recurrence after FIGO stage I endometrial cancer - Longitudinal study from 1969 to 1990 in Freiburg
    Ladner, HA
    Pfleiderer, A
    Bahnsen, J
    Ladner, S
    Karck, U
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2001, 61 (04) : 173 - 181
  • [35] Is carboplatin as effective as radiotherapy for the adjuvant treatment of stage I seminoma?
    Carsten Bokemeyer
    Nature Clinical Practice Urology, 2005, 2 : 586 - 587
  • [36] Survival Impact of Postoperative Adjuvant Radiotherapy for Treatment of Advanced Stage Maxillary Sinus Cancer Patients
    Nandwana, Upendra
    Verma, Manoj
    Soni, Tej Prakash
    Jakhotia, Naresh
    Patni, Nidhi
    Gupta, Anil Kumar
    Sharma, Lalit Mohan
    Pasricha, Rajesh
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2018, 12 (02) : XC1 - XC3
  • [37] Time to Recurrence After Primary Treatment Predicts Survival of Patients with Stage I-II Endometrial Cancer
    Laser, B.
    Robbins, J. R.
    Yechieli, R.
    Fatteh, S.
    Rasool, N.
    Mahan, M.
    Munkarah, A.
    Elshaikh, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S472 - S472
  • [38] Is carboplatin as effective as radiotherapy for the adjuvant treatment of stage I seminoma?
    Bokemeyer, C
    NATURE CLINICAL PRACTICE UROLOGY, 2005, 2 (12): : 586 - 587
  • [39] Cost-effectiveness of radical hysterectomy with adjuvant radiotherapy versus radical radiotherapy for FIGO stage IIB cervical cancer
    Chai, Yanlan
    Wang, Juan
    Wang, Tao
    Shi, Fan
    Wang, Jiquan
    Su, Jin
    Yang, Yunyi
    Zhou, Xi
    Ma, Hailin
    He, Bin
    Liu, Zi
    ONCOTARGETS AND THERAPY, 2016, 9 : 349 - 354
  • [40] The role of adjuvant radiotherapy in carcinoma of the endometrium - Results in 550 patients with pathologic stage I disease
    Irwin, C
    Levin, W
    Fyles, A
    Pintilie, M
    Manchul, L
    Kirkbride, P
    GYNECOLOGIC ONCOLOGY, 1998, 70 (02) : 247 - 254